ModRNA-based Direct Programming of Universal Donor hiPSCs into Immune Evasive Beta Cells
ModRNA-based Direct Programming of Universal Donor hiPSCs into Immune Evasive Beta Cells
批准号:
10774361
负责人:
Xiaojun Lian
金额:
$24.05万
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
未结题
起止时间:
2023-05-01 至 2025-04-30
关键词:
AccelerationAffectBeta CellBiological AssayBlood GlucoseC-PeptideCRISPR-mediated transcriptional activationCell Differentiation processCell LineCell TherapyCell TransplantationCellsCellular biologyChemicalsClone CellsCloningComplementary DNACoupledCytolysisDefectDevelopmentDiabetes MellitusElectron MicroscopeEngineeringExhibitsGene ExpressionGenerationsGenesGenomicsGlucoseGoalsGrowth FactorGuide RNAHSF1Homologous TransplantationHumanImageImmuneImmune EvasionImmunologic TestsIn VitroIndividualInsulin-Dependent Diabetes MellitusIslet CellMeasuresMediatingMediator of activation proteinMetabolic DiseasesMusMutagenesisNatural Killer CellsPancreasPatientsPersonsPopulationPropertyPublic HealthRNAResearch PersonnelSpeedStructure of beta Cell of isletSystemT-LymphocyteTechnologyTestingTherapeuticTimeTime StudyTranscription Initiation SiteTransfectionTransfer RNATransplantationUnited StatesViral Vectoractivin Aaptamerautoimmune pathogenesiscostdelivery vehicledesigndiabeticdifferentiation protocoldirected differentiationdonor stem cellendocrine pancreas developmentexperimental studyfunctional restorationgenomic locushumanized mousein vivoinduced pluripotent stem cellinnovationinsulin secretionmouse modelnovelnovel therapeuticsoligodendrocyte progenitoroverexpressionp65programsscreeningsingle-cell RNA sequencingstem cellstranscription factorvector
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary
Pancreatic beta cells derived from human induced pluripotent stem cells (hiPSCs) hold the potential to
dramatically change the treatment of type 1 diabetes (T1D). To realize the therapeutic application of these
cells, however, we need to develop a robust and rapid means for generating beta cells. Here, the investigators
propose a novel paradigm for direct programming of hiPSC into beta cells via CRISPR activation of
transcription factors (TFs). These CRISPR activation effectors will be delivered into hiPSCs using modRNAs,
avoiding genomic integrations by previous viral vector approach. Furthermore, the investigators will also use
recent advances in gene editing to generate universal donor hiPSC clones, which will be used for beta cell
programming. These universal donor beta cells can be used for allogeneic transplantation without immune
rejections.
First, the investigators will investigate optimal msgRNAs for activation of pancreatic TFs in hiPSCs. Next, they
will use a multiplexed msgRNA expression system to express all msgRNAs to activate numerous msgRNAs
coupled with the dCas9 activator modRNA to study beta cell programming. In Aim 3, the investigators will
generate immune-privileged beta cells via programming of universal donor hiPSCs. Universal donor hiPSCs
will be generated by removing B2M to inhibit T cell-mediated rejection, and by overexpression of HLA-E trimer
to avoid the natural killer (NK) cell-mediated lysis of transplanted cells. The investigators will then use in vitro
and in vivo assays to characterize programmed beta cells. For in vitro experiments, the investigator will
perform glucose stimulated insulin secretion assay. For in vivo assays, the investigator will use the NRG Akita
mice to test whether programmed beta cells can reverse diabetes in vivo. The investigator will also use
humanized NSG mice to study whether programmed beta cells from universal donor hiPSCs exhibit immune
evasive properties as compared to cells generated from normal hiPSCs.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金